93.47
BATS BZX Real-Time Price
As of 1:24pm ET
 -0.67 / -0.71%
Today’s Change
62.66
Today|||52-Week Range
97.86
+5.57%
Year-to-Date
Where Will Gilead Sciences Be in 10 Years?
Feb 19 / MotleyFool.com - Paid Partner Content
AbbVie Is a Dividend Growth Stock at a Bargain Price
Feb 12 / MotleyFool.com - Paid Partner Content
17 Consumer Groups and Unions Ask FTC to Block AbbVie's Acquisition of Allergan
Feb 18 / MotleyFool.com - Paid Partner Content
With Solid Fourth Quarter Results, AbbVie Shows That Its Growth Days Are Far From Over
Feb 11 / MotleyFool.com - Paid Partner Content
Better Buy: AbbVie vs. Eli Lilly
Feb 18 / MotleyFool.com - Paid Partner Content
Better Buy: Pfizer vs. AbbVie
Feb 11 / MotleyFool.com - Paid Partner Content
Better Buy: AbbVie vs. Gilead Sciences
Feb 16 / MotleyFool.com - Paid Partner Content
Is Takeda Pharmaceutical Company Stock a Buy?
Feb 11 / MotleyFool.com - Paid Partner Content
3 High-Yielding U.S. Pharmaceutical Companies to Consider
Feb 15 / MotleyFool.com - Paid Partner Content
How Allergan Beat Estimates in What's Likely Its Last Quarterly Update
Feb 10 / MotleyFool.com - Paid Partner Content
Could This Cancer Drug Developer’s Stock Make You Rich?
Feb 14 / MotleyFool.com - Paid Partner Content
Allergan Reports Fourth-Quarter 2019 Results That Plow Past Expectations
Feb 10 / MotleyFool.com - Paid Partner Content
3 Reasons AbbVie Is a Better Bargain Than You Might Think
Feb 14 / MotleyFool.com - Paid Partner Content
AbbVie Inc (ABBV) Q4 2019 Earnings Call Transcript
Feb 07 / MotleyFool.com - Paid Partner Content
Allergan Pins Hopes on Millennials With Juvederm Marketing
Feb 12 / MotleyFool.com - Paid Partner Content
Here's How AbbVie Impressed Investors With Its Q4 Update
Feb 07 / MotleyFool.com - Paid Partner Content
Gilead Sciences Looks Ready to Outpace AbbVie
Feb 12 / MotleyFool.com - Paid Partner Content
AbbVie Reports Estimate-Beating Fourth-Quarter Earnings Results
Feb 07 / MotleyFool.com - Paid Partner Content